Novabridge Biosciences (NBP) Competitors

Novabridge Biosciences logo
$0.82 +0.03 (+3.89%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+1.67%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NBP vs. LYEL, RZLT, YDES, SRZN, and ALEC

Should you buy Novabridge Biosciences stock or one of its competitors? Novabridge Biosciences's main competitors and comparable companies include Lyell Immunopharma (LYEL), Rezolute (RZLT), YD Bio (YDES), Surrozen (SRZN), and Alector (ALEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Novabridge Biosciences compare to Lyell Immunopharma?

Novabridge Biosciences (NASDAQ:NBP) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Novabridge Biosciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -1,701,066.75%. Novabridge Biosciences' return on equity of 0.00% beat Lyell Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Novabridge BiosciencesN/A N/A N/A
Lyell Immunopharma -1,701,066.75%-107.62%-80.01%

Novabridge Biosciences has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

38.4% of Novabridge Biosciences shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 22.1% of Novabridge Biosciences shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novabridge Biosciences has higher revenue and earnings than Lyell Immunopharma. Novabridge Biosciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novabridge Biosciences$3.89M24.52-$46.27M-$0.36N/A
Lyell Immunopharma$40K8,403.63-$274.45M-$12.56N/A

In the previous week, Lyell Immunopharma had 8 more articles in the media than Novabridge Biosciences. MarketBeat recorded 8 mentions for Lyell Immunopharma and 0 mentions for Novabridge Biosciences. Novabridge Biosciences' average media sentiment score of 1.79 beat Lyell Immunopharma's score of -0.10 indicating that Novabridge Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Novabridge Biosciences Very Positive
Lyell Immunopharma Neutral

Novabridge Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 994.49%. Lyell Immunopharma has a consensus price target of $40.00, suggesting a potential upside of 192.61%. Given Novabridge Biosciences' higher possible upside, analysts clearly believe Novabridge Biosciences is more favorable than Lyell Immunopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novabridge Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lyell Immunopharma
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Summary

Novabridge Biosciences beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

How does Novabridge Biosciences compare to Rezolute?

Novabridge Biosciences (NASDAQ:NBP) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Novabridge Biosciences presently has a consensus target price of $9.00, suggesting a potential upside of 994.49%. Rezolute has a consensus target price of $11.67, suggesting a potential upside of 190.94%. Given Novabridge Biosciences' higher probable upside, analysts plainly believe Novabridge Biosciences is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novabridge Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Rezolute had 10 more articles in the media than Novabridge Biosciences. MarketBeat recorded 10 mentions for Rezolute and 0 mentions for Novabridge Biosciences. Novabridge Biosciences' average media sentiment score of 1.79 beat Rezolute's score of 0.05 indicating that Novabridge Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Novabridge Biosciences Very Positive
Rezolute Neutral

Novabridge Biosciences' return on equity of 0.00% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
Novabridge BiosciencesN/A N/A N/A
Rezolute N/A -72.24%-65.90%

38.4% of Novabridge Biosciences shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 22.1% of Novabridge Biosciences shares are held by company insiders. Comparatively, 15.1% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novabridge Biosciences has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Novabridge Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novabridge Biosciences$3.89M24.52-$46.27M-$0.36N/A
RezoluteN/AN/A-$77.59M-$0.76N/A

Novabridge Biosciences has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Summary

Novabridge Biosciences beats Rezolute on 9 of the 13 factors compared between the two stocks.

How does Novabridge Biosciences compare to YD Bio?

Novabridge Biosciences (NASDAQ:NBP) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
Novabridge BiosciencesN/A N/A N/A
YD Bio N/A N/A N/A

YD Bio has lower revenue, but higher earnings than Novabridge Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novabridge Biosciences$3.89M24.52-$46.27M-$0.36N/A
YD BioN/AN/AN/AN/AN/A

Novabridge Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 994.49%. Given Novabridge Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Novabridge Biosciences is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novabridge Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

38.4% of Novabridge Biosciences shares are owned by institutional investors. 22.1% of Novabridge Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, YD Bio had 3 more articles in the media than Novabridge Biosciences. MarketBeat recorded 3 mentions for YD Bio and 0 mentions for Novabridge Biosciences. Novabridge Biosciences' average media sentiment score of 1.79 beat YD Bio's score of 0.62 indicating that Novabridge Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Novabridge Biosciences Very Positive
YD Bio Positive

Novabridge Biosciences has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, YD Bio has a beta of -1.2, suggesting that its stock price is 220% less volatile than the broader market.

Summary

Novabridge Biosciences beats YD Bio on 8 of the 9 factors compared between the two stocks.

How does Novabridge Biosciences compare to Surrozen?

Novabridge Biosciences (NASDAQ:NBP) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

38.4% of Novabridge Biosciences shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 22.1% of Novabridge Biosciences shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Novabridge Biosciences has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company Net Margins Return on Equity Return on Assets
Novabridge BiosciencesN/A N/A N/A
Surrozen -2,885.33%N/A -112.96%

Novabridge Biosciences has higher revenue and earnings than Surrozen. Novabridge Biosciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novabridge Biosciences$3.89M24.52-$46.27M-$0.36N/A
Surrozen$3.48M164.20-$242.03M-$43.21N/A

Novabridge Biosciences has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

In the previous week, Surrozen had 14 more articles in the media than Novabridge Biosciences. MarketBeat recorded 14 mentions for Surrozen and 0 mentions for Novabridge Biosciences. Novabridge Biosciences' average media sentiment score of 1.79 beat Surrozen's score of 0.07 indicating that Novabridge Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Novabridge Biosciences Very Positive
Surrozen Neutral

Novabridge Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 994.49%. Surrozen has a consensus target price of $61.75, suggesting a potential upside of 105.97%. Given Novabridge Biosciences' higher possible upside, equities analysts clearly believe Novabridge Biosciences is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novabridge Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Novabridge Biosciences beats Surrozen on 8 of the 14 factors compared between the two stocks.

How does Novabridge Biosciences compare to Alector?

Alector (NASDAQ:ALEC) and Novabridge Biosciences (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Alector presently has a consensus price target of $5.10, suggesting a potential upside of 99.22%. Novabridge Biosciences has a consensus price target of $9.00, suggesting a potential upside of 994.49%. Given Novabridge Biosciences' higher probable upside, analysts plainly believe Novabridge Biosciences is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43
Novabridge Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Alector had 7 more articles in the media than Novabridge Biosciences. MarketBeat recorded 7 mentions for Alector and 0 mentions for Novabridge Biosciences. Novabridge Biosciences' average media sentiment score of 1.79 beat Alector's score of 1.05 indicating that Novabridge Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Alector Positive
Novabridge Biosciences Very Positive

85.8% of Alector shares are owned by institutional investors. Comparatively, 38.4% of Novabridge Biosciences shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 22.1% of Novabridge Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Novabridge Biosciences has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Novabridge Biosciences has lower revenue, but higher earnings than Alector. Novabridge Biosciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.05M18.11-$142.93M$0.357.31
Novabridge Biosciences$3.89M24.52-$46.27M-$0.36N/A

Alector has a net margin of 23.87% compared to Novabridge Biosciences' net margin of 0.00%. Alector's return on equity of 112.21% beat Novabridge Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alector23.87% 112.21% 18.37%
Novabridge Biosciences N/A N/A N/A

Summary

Alector beats Novabridge Biosciences on 10 of the 16 factors compared between the two stocks.

Get Novabridge Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBP vs. The Competition

MetricNovabridge BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$91.81M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / Sales24.5215.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book0.414.184.453.72
Net Income-$46.27M-$24.15M$3.52B$393.10M
7 Day Performance-4.49%-7.81%-5.93%-5.77%
1 Month Performance-34.74%-5.99%-4.58%-7.14%
1 Year PerformanceN/A-8.09%-1.94%-7.46%

Novabridge Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBP
Novabridge Biosciences
2.8768 of 5 stars
$0.82
+3.9%
$9.00
+994.5%
N/A$91.81M$3.89MN/A30
LYEL
Lyell Immunopharma
3.1528 of 5 stars
$14.30
-8.6%
$40.00
+179.7%
-21.5%$384.52M$40KN/A161
RZLT
Rezolute
2.8101 of 5 stars
$3.65
-5.7%
$11.22
+207.5%
-60.8%$374.34MN/AN/A58
YDES
YD Bio
1.3677 of 5 stars
$4.88
-6.2%
N/AN/A$367.75MN/AN/A14
SRZN
Surrozen
2.6213 of 5 stars
$31.61
-0.2%
$61.75
+95.3%
+134.2%$367.70M$3.48MN/A44

Related Companies and Tools


This page (NASDAQ:NBP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners